Diagnostic probes and therapeutics targeting upa and upar
CA 2406882 A1 · Owner: Angstrom Pharmaceuticals, Inc. · Inventors: Jones, Terence R.; Mazar, Andrew P.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A uPAR-targeting protein or peptide is diagnostically or therapeutically labeled and used in methods of diagnosis of therapy. The labeled protein or peptide preferably has the following properties: it comprises at least 38 amino acid residues, including residues 13-30 of the uPAR-binding site of uPA; competes with labeled DFP-uPA for binding to a cell or molecule that has a binding site for uPA, and has an IC50 value of about 10 nM or less; and is not a fusion protein wherein the uPA peptide is fused to another non-uPA protein or peptide. Preferred molecules are uPA scuPA, tcuPA, an N-terminal fragment , of uPA residues 1-135, an N-terminal fragment of uPA residues 1-143, an N-, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 27, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 27, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 27, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.